Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POVAN (pyrvinium pamoate) is an oral suspension anthelmintic indicated for the treatment of pinworm (Enterobius vermicularis) infections. The drug works by disrupting the energy metabolism of parasitic worms, leading to their immobilization and elimination. It represents a classic antiparasitic agent with a narrow but well-defined therapeutic niche.
Pre-Launch
As a pre-launch product from Pfizer, this represents an early-stage commercial build with opportunity to establish market presence in a historically underserved antiparasitic category.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on POVAN offers exposure to launch-phase strategy, pediatric market dynamics, and niche therapeutic positioning within a major pharmaceutical organization. Career growth depends on successful market penetration and establishing Pfizer as a key player in the antiparasitic space.
Brand ManagerField Sales Representative
Worked on POVAN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.